VEGF is a key regulator of angiogenesis and the humanised VEGF monoclonal antibody bevacizumab has been shown to prolong survival when given in combination with chemotherapy in NSCLC (Sandler et al, 2006). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.